BD (Becton, Dickinson and Company) and Vancive Medical Technologies™, an Avery Dennison business, today launched a line of transparent vascular dressings with chlorhexidine gluconate (CHG) antimicrobial preservative that are designed to enhance patient care and be easy for clinicians to apply and remove.
The new BD ChloraShield™ dressings, which feature BeneHold™ CHG, an innovative adhesive technology from Vancive Medical Technologies, comfortably secure the dressing to the skin, absorb fluids and protect the site from external contaminants. The CHG incorporated within the adhesive preserves the dressing from microbial growth, making them well-suited for catheter insertion sites. The Infusion Nurses Society recently released guidelines recommending the use of CHG dressings.1 BD is the exclusive distributor of the dressings worldwide.
“The combination of vascular access expertise from BD, infection prevention expertise from the CareFusion acquisition and CHG adhesive technology from Vancive Medical Technologies creates a powerful combination for a new vascular access product,” said Stephen Hartley, global vice president of Infection Prevention for BD. “The new ChloraShield IV dressings complete BD’s portfolio to offer a comprehensive set of products for vascular access procedures, including skin prep, catheters, connectors and flush products.”
BD ChloraShield dressings are available in a variety of designs including bordered and non-bordered as well as sizes commonly used for peripheral IVs and PICCs.
“BeneHold CHG adhesive technology is well-suited for vascular access dressings,” said Kirsten Newquist general manager for Vancive Medical Technologies. “The collaboration with BD brings together complementary expertise from both companies and we look forward to expanding the product offerings in the future.”
BD and Vancive Medical Technologies will showcase the new BD ChloraShield dressings in booth #423 at the 30th annual Association for Vascular Access Conference, being held Sept. 16-19 in Orlando, Fla. To learn more about ChloraShield IV dressings with CHG antimicrobial visit, bd.com/ChloraShieldIV.
BD (bd.com) is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, optimize respiratory care and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 45,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health.
About Vancive Medical Technologies
Vancive Medical Technologies (vancive.averydennison.com) is a medical technology company with more than three decades of expertise in adhesive chemistries and material technologies for medical applications using pressure sensitive adhesives. The company's applications and technologies are an integral part of products that are in daily use in medical facilities throughout the world. Through long-term relationships with original equipment manufacturers, industry-specific converters and leading universities, Vancive Medical Technologies continually finds new ways to develop products that can improve patient care. Vancive Medical Technologies is an Avery Dennison business headquartered in Chicago, Illinois.
About Avery Dennison
Avery Dennison (averydennison.com) is a global leader in labeling and packaging materials and solutions. The company’s applications and technologies are an integral part of products used in every major market and industry. With operations in more than 50 countries and more than 25,000 employees worldwide, Avery Dennison serves customers with insights and innovations that help make brands more inspiring and the world more intelligent. Headquartered in Glendale, California, the company reported sales of $6 billion in 2015.
BD Contact: Monique N. Dolecki - BD Investor Relations
P: 201 847 5378 - E: monique_dolecki[.]bd.com
Andrew Deckert - Global Marketing Communications Manager
P: 224 374 2109 - E: andrew.deckert[.]averydennison.com
Barbara Van Rymenam - Global Director, CHG Program
P: +32(0)497 103233 - E: barbara.van.rymenam[.]eu.averydennison.com